Steven D Averbuch
Overview
Explore the profile of Steven D Averbuch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schiller J, Averbuch S, Berg C
JCO Oncol Pract
. 2020 Sep;
16(12):775-778.
PMID: 32915709
No abstract available.
2.
Tsimberidou A, Levit L, Schilsky R, Averbuch S, Chen D, Kirkwood J, et al.
J Immunother Cancer
. 2018 Oct;
6(1):108.
PMID: 30340549
Purpose: To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. Methods: ASCO and the Society for Immunotherapy...
3.
Tsimberidou A, Levit L, Schilsky R, Averbuch S, Chen D, Kirkwood J, et al.
J Clin Oncol
. 2018 Oct;
37(1):72-80.
PMID: 30339040
Purpose: To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. Methods: ASCO and the Society for Immunotherapy...
4.
Trusheim M, Burgess B, Hu S, Long T, Averbuch S, Flynn A, et al.
Nat Rev Drug Discov
. 2011 Nov;
10(11):817-33.
PMID: 22037040
Co-developing a drug with a diagnostic to create a stratified medicine - a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such...
5.
LoRusso P, Anderson A, Boerner S, Averbuch S
Clin Cancer Res
. 2010 Dec;
16(24):5956-62.
PMID: 21169248
Advances in our knowledge of the molecular mechanisms involved in cancer biology have contributed to an increase in novel target-specific oncology therapeutics. Unfortunately, clinical development of new drugs is an...
6.
LoRusso P, Schnipper L, Stewart D, Boerner S, Averbuch S, Wolf W
Clin Cancer Res
. 2010 Dec;
16(24):5951-5.
PMID: 21169247
Efforts to unravel the complex biology that is necessary to develop new therapies best suited for an individual with cancer are at a crossroads with a strained health care system...
7.
Herbst R, Giaccone G, Schiller J, Natale R, Miller V, Manegold C, et al.
J Clin Oncol
. 2004 Mar;
22(5):785-94.
PMID: 14990633
Purpose: Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may enhance antitumor efficacy of cytotoxics, and combination with...
8.
Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V, et al.
J Clin Oncol
. 2004 Mar;
22(5):777-84.
PMID: 14990632
Purpose: The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE) to standard first-line...
9.
Averbuch S
Clin Lung Cancer
. 2003 Dec;
5 Suppl 1:S5-S10.
PMID: 14641988
The ErbB family of receptor tyrosine kinases, of which the epidermal growth factor receptor (EGFR) is the prototype, is associated with the formation and malignant progression of most of the...
10.
Kris M, Natale R, Herbst R, Lynch Jr T, Prager D, Belani C, et al.
JAMA
. 2003 Oct;
290(16):2149-58.
PMID: 14570950
Context: More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth...